A review of the efficacy and tolerability of antipsychotic long-acting injections

Abstract

The formulation of long‐acting injections (LAIs) as a method of delivering antipsychotics can be used to improve adherence, particularly in those unintentionally non‐adherent. Here, the authors review the efficacy and tolerability of first‐generation antipsychotic (FGA) and second‐generation antipsychotic (SGA) LAIs, analyse drug cost, give guidance on initiation regimens for SGA LAIs and discuss the future for these drugs.

Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia

“…Injection-site reaction is a common AE associated with LAIs 2 , 17 , 18 and therefore was evaluated in greater detail. All ISRs associated with the AL NCD , placebo IM, AL 441 mg, and AL 882 mg injections were mild to moderate in severity.…”

“… 1 Long-acting injectables are often started during acute episodes of schizophrenia in the hospital setting with the premise that the patient may be more likely to stay on medication after discharge. 2 …”

Modelling intramuscular drug fate in vitro with tissue-relevant biomimetic hydrogels

“…epinephrine) or as long-acting injectables (LAIs) which gradually release drug in a controlled manner over weeks or months ( e.g. haloperidol decanoate) ( Gu et al, 1999 ; Whyte and Parker, 2016 ). Despite the large number of drugs approved by regulators for IM injection, there is limited knowledge of how these drugs interact with the IM environment, i.e.…”